Clinical trial

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-12-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2017-12-01Date precision: day

Registry last updated2023-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Multiple Sclerosis, Secondary Progressiveunresolved

Multiple Sclerosis, Primary Progressiveunresolved

Interventions

Placebo (Sterile diluent)DRUG

Sponsors & collaborators

Johns Hopkins Universitylead sponsor

United States Department of Defensecollaborator

Mapped research locations

BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02988401 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.